Nanomedex, Inc.

Middleton, WI 53562

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $3.15MM
First Award Date 09/01/04
Most Recent Award Date 05/01/11

Key Personnel

Last Name Name Awards Contact
Modell Jerome Herbert Modell 3
Cooper David Lynn Cooper 2

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 05/01/11 - 04/30/13

DESCRIPTION (provided by applicant): Propofol is the largest selling, intravenous general anesthetic that may have several adverse effects due to its lipophilicity and need to be formulated in Intralipid. We propose to develop a patented microemulsion of propofol in which the lipophilicity of propofol is leveraged to serve dual roles as both th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 05/01/10 - 04/30/11

DESCRIPTION (provided by applicant): Propofol is the largest selling, intravenous general anesthetic that may have several adverse effects due to its lipophilicity and need to be formulated in Intralipid. We propose to develop a patented microemulsion of propofol in which the lipophilicity of propofol is leveraged to serve dual roles as both th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/07 - 03/31/08

DESCRIPTION (provided by applicant): Propofol is the largest selling, intravenous general anesthetic with domestic annual sales in excess of $500 million due to several favorable characteristics of this anesthetic and has an expected annual growth rate of 19%. However, a primary drawback of propofol (2,6-diisopropylphenol) revolves around this d...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/07/06 - 03/31/07

DESCRIPTION (provided by applicant): Propofol is the largest selling, intravenous general anesthetic with domestic annual sales in excess of $500 million due to several favorable characteristics of this anesthetic and has an expected annual growth rate of 19%. However, a primary drawback of propofol (2,6-diisopropylphenol) revolves around this d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 02/28/05

DESCRIPTION (provided by applicant): Domestic propofol sales exceed $500 million annually and continue to increase due to a shift towards ambulatory surgery. This intravenous anesthetic exists as an oil and necessitates dispersion in a soybean macroemulsion (i.e., Intralipid). This formulation (e.g., Diprivan) has a number of disadvantages ov...